Argiriou Mihalis, Kolokotron Styliani-Maria, Sakellaridis Timothy, Argiriou Orestis, Charitos Christos, Zarogoulidis Paul, Katsikogiannis Nikolaos, Kougioumtzi Ioanna, Machairiotis Nikolaos, Tsiouda Theodora, Tsakiridis Kosmas, Zarogoulidis Konstantinos
1 Cardiac Surgery Department, Transplantation Unit, "Evangelismos" Hospital, Athens, Greece ; 2 University of Ioannina School of Medicine, Ioannina, Greece ; 3 Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece ; 4 Surgery Department (NHS), University General Hospital of Alexandroupolis, Alexandroupolis, Greece ; 5 Internal Medicine Department, Theageneio Anticancer Hospital, Thessaloniki, Greece ; 6 Cardiothoracic Surgery Department, "Saint Luke" Private Hospital, Panorama, Thessaloniki, Greece.
J Thorac Dis. 2014 Mar;6 Suppl 1(Suppl 1):S52-9. doi: 10.3978/j.issn.2072-1439.2013.10.26.
Right heart failure (RHF) is a frequent complication following left ventricular assist device (LVAD) implantation. The incidence of RHF complicates 20-50% (range, 9-44%) of cases and is a major factor of postoperative morbidity and mortality. Unfortunately, despite the fact that many risk factors contributing to the development of RHF after LVAD implantation have been identified, it seems to be extremely difficult to avoid them. Prevention of RHF consists of the management of the preload and the afterload of the right ventricle with optimum inotropic support. The administration of vasodilators designed to reduce pulmonary vascular resistance is standard practice in most centers. The surgical attempt of implantation of a right ventricular assist device does not always resolve the problem and is not available in all cardiac surgery centers.
右心衰竭(RHF)是左心室辅助装置(LVAD)植入术后常见的并发症。RHF的发生率在20%至50%(范围为9%至44%)的病例中较为复杂,是术后发病率和死亡率的主要因素。不幸的是,尽管已经确定了许多导致LVAD植入术后RHF发生的危险因素,但似乎极难避免这些因素。预防RHF包括通过最佳的正性肌力支持来管理右心室的前负荷和后负荷。在大多数中心,使用旨在降低肺血管阻力的血管扩张剂是标准做法。植入右心室辅助装置的手术尝试并不总能解决问题,而且并非所有心脏外科中心都能进行。